Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.80 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.80 |
| ▸ | F3 | P13726 | 5/20 | 0.80 |
| ▸ | POLB | P06746 | 3/20 | 0.80 |
| ▸ | USP7 | Q93009 | 3/20 | 0.80 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.80 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.80 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.80 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.80 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.80 |
| ▸ | PTPRC | P08575 | 2/20 | 0.80 |
| ▸ | PTPRF | P10586 | 2/20 | 0.80 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.80 |
| ▸ | CES1 | P23141 | 2/20 | 0.80 |
| ▸ | ACP1 | P24666 | 2/20 | 0.80 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.80 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.80 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.80 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.80 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18704446 | 1.00 | PTPN1 (0.80) | PTPN1PTPN2F3POLBUSP7 | |
| SCHEMBL9880211 | 1.00 | PTPN1 (0.80) | PTPN1PTPN2F3POLBUSP7 | |
| SCHEMBL18712554 | 1.00 | PTPN1 (0.80) | PTPN1PTPN2F3POLBUSP7 | |
| SCHEMBL10322381 | 0.91 | PTPN1 (0.75) | PTPN1PTPN2F3POLBUSP7 | |
| SCHEMBL29935128 | 0.91 | PTPN1 (0.66) | PTPN1PTPN2F3POLBUSP7 | |
| SCHEMBL18712775 | 0.90 | PTPN1 (0.81) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL24916648 | 0.89 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL22009261 | 0.89 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL20904290 | 0.89 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL21892159 | 0.89 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 544 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087678-A1 | TREATMENT FOR RENAL DISORDERS | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087679-A1 | TREATMENT FOR DISORDERS OF THE KIDNEY OR SPLEEN | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4731257-A1 | CONJUGATES OF SAPONIN AND ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Sapreme Technologies B.V. (NL) | 2026-04-29 | — | — | EP | claimed |
| EP-4731261-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Sapreme Technologies B.V. (NL) | 2026-04-29 | — | — | EP | claimed |
| EP-4719478-A1 | IMPROVED TREATMENT REGIMENS FOR THERAPEUTIC EFFECTOR COMPONENTS THAT ACT VIA AN INTRACELLULAR MOLECULAR TARGET | Sapreme Technologies B.V. (NL) | 2026-04-08 | — | — | EP | claimed |
| EP-3915587-B1 | IMPROVED CELL-TARGETING BINDING MOLECULE | SAPREME TECH BV (NL) | 2026-03-25 | — | — | EP | claimed |
| US-20260077055-A1 | COMPOSITIONS OF POLYPLEXES AND SAPONINS | SAPREME TECH BV (NL) | 2026-03-19 | — | — | US | claimed |
| EP-4652450-A1 | METHODS OF QUANTIFYING SAPONINS PRESENT IN PARTICLES COMPRISING SAPONIN AND LIPID | Novavax AB (SE) | 2025-11-26 | — | — | EP | claimed |
| WO-2003007975-A1 | CURCUMINOID COMPOSITIONS EXHIBITING SYNERGISTIC INHIBITION OF THE EXPRESSION AND/OR ACTIVITY OF CYCLOOXYGENASE-2 | METAPROTEOMICS, LLC (US) | 2003-01-30 | — | — | WO | claimed |
| US-20020077350-A1 | Compositions exhibiting synergistic inhibition of the expression and/or activity of clyclooxygenase-2 | ASHNI NATURACEUTICALS, INC. | 2002-06-20 | — | — | US | claimed |
| US-20020068098-A1 | Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2 | ASHNI NATURACEUTICALS, INC. | 2002-06-06 | — | — | US | claimed |
| WO-2002009698-A1 | COMPOSITIONS EXHIBITING SYNERGISTIC INHIBITION OF THE EXPRESSION AND/OR ACTIVITY OF CYCLOOXYGENASE-2 | ASHNI NATURACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | claimed |
| EP-0996451-A4 | TRITERPENE SAPONIN ANALOGS HAVING ADJUVANT AND IMMUNOSTIMULATORY ACTIVITY | GALENICA PHARMACEUTICALS INC (US) | 2001-04-18 | — | — | EP | claimed |
| EP-0996451-A1 | TRITERPENE SAPONIN ANALOGS HAVING ADJUVANT AND IMMUNOSTIMULATORY ACTIVITY | Galenica Pharmaceuticals, Inc. (US) | 2000-05-03 | — | — | EP | claimed |
| US-5977081-A | PLANT EXTRACT; ADJUST IMMUNOLOGY RESPONSE | GALENICA PHARMACEUTICALS, INC. (US) | 1999-11-02 | — | — | US | claimed |
| WO-1998052573-A1 | TRITERPENE SAPONIN ANALOGS HAVING ADJUVANT AND IMMUNOSTIMULATORY ACTIVITY | GALENICA PHARMACEUTICALS, INC. (US) | 1998-11-26 | — | — | WO | claimed |
| CN-1130910-A | Hapten-labelled peptides | BOEHRINGER MANNHEIM GMBH (DE) | 1996-09-11 | — | — | CN | claimed |
| US-4606911-A | PENTACYCLIC ACID TRITERPENES | ROHTO PHARMACEUTICAL CO. LTD. (JP) | 1986-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077055-A1 | COMPOSITIONS OF POLYPLEXES AND SAPONINS | GAA, EEA1, RNASE1 | PTPN1 2698/4885PTPN2 3202/4885F3 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.